← back to search

Andrei A. Ivanov

Gazprom (Russia) · RU
Area of research
Molecular Biology · Physiology
Research interest
Research interests include Adenosine and Purinergic Signaling, Receptor Mechanisms and Signaling, Computational Drug Discovery Methods, and Pharmacological Receptor Mechanisms and Effects.
h-index
27
citations
3,349
works
138
NIH funding
primary concept
email

Recent publications

Pharmacological suppression of the OTUD4/CD73 proteolytic axis revives antitumor immunity against immune-suppressive breast cancers
Journal of Clinical Investigation 2024cited by 27position: middledoi
Systematic discovery of mutation-directed neo-protein-protein interactions in cancer
Cell 2022cited by 74position: middledoi
Surfaceome profiling to reveal unique therapeutic vulnerabilities in transcriptional subtypes of small cell lung cancer (SCLC).
Journal of Clinical Oncology 2022cited by 3position: middledoi
An expanded universe of cancer targets
Cell 2021cited by 219position: middledoi
YAP1 Expression in SCLC Defines a Distinct Subtype With T-cell–Inflamed Phenotype
Journal of Thoracic Oncology 2020cited by 165position: middledoi
Hypomorph mutation-directed small-molecule protein-protein interaction inducers to restore mutant SMAD4-suppressed TGF-β signaling
Cell chemical biology 2020cited by 38position: middledoi
High expression of MKK3 is associated with worse clinical outcomes in African American breast cancer patients
Journal of Translational Medicine 2020cited by 28position: lastdoi
In vivo screening identifies GATAD2B as a metastasis driver in KRAS-driven lung cancer
Nature Communications 2018cited by 46position: middledoi
The OncoPPi network of cancer-focused protein–protein interactions to inform biological insights and therapeutic strategies
Nature Communications 2017cited by 221position: middledoi
The OncoPPi Portal: an integrative resource to explore and prioritize protein–protein interactions for cancer target discovery
Bioinformatics 2017cited by 54position: firstdoi
OncoPPi-informed discovery of mitogen-activated protein kinase kinase 3 as a novel binding partner of c-Myc
Oncogene 2017cited by 40position: firstdoi
AKT1, LKB1, and YAP1 Revealed as MYC Interactors with NanoLuc-Based Protein-Fragment Complementation Assay
Molecular Pharmacology 2017cited by 33position: middledoi
Enabling systematic interrogation of protein–protein interactions in live cells with a versatile ultra-high-throughput biosensor platform
Journal of Molecular Cell Biology 2015cited by 40position: middledoi
Targeting protein–protein interactions as an anticancer strategy
Trends in Pharmacological Sciences 2013cited by 399position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

Haian Fu · Emory University12 papers (2013–2024)Fadlo R. Khuri · Emory University8 papers (2013–2022)Xiulei Mo · Emory University8 papers (2015–2022)Yuhong Du · North University of China7 papers (2015–2022)Lee Cooper · Chan Zuckerberg Initiative (United States)5 papers (2017–2022)Carlos S. Moreno · Emory University4 papers (2017–2022)Qiankun Niu · Emory University4 papers (2017–2022)Margaret A. Johns · Emory University4 papers (2017–2017)Valentina González-Pecchi · Universidad Católica de la Santísima Concepción3 papers (2017–2017)Xuan Yang · Tianjin University3 papers (2020–2022)Taofeek K. Owonikoko · New Mexico Cancer Center3 papers (2020–2022)Brian Revennaugh · Emory University2 papers (2017–2017)Yiu Huen Tsang · Oregon Health & Science University2 papers (2018–2022)Cong Tang · Tianjin University2 papers (2020–2022)Wei Zhou · Hebei Medical University2 papers (2017–2022)Alafate Wahafu · Emory University2 papers (2020–2022)Lauren Rusnak · Emory University2 papers (2017–2017)Suresh S. Ramalingam · Emory University2 papers (2020–2022)Qi Qi · Institute of Pharmacology2 papers (2017–2017)Gordon B. Mills · Massachusetts General Hospital2 papers (2018–2022)